







A phase III multi-center randomized trial:

VItamin C in Thermal injuRY: The VICToRY Trial

Clinical trials.gov ID #NCT04138394

Sponsor: Dr. Daren Heyland

Principal Investigators:

Dr. Daren Heyland, Critical Care Department, Queen's University, Kingston, ON, Canada

Dr. Christian Stoppe, Anesthesiology Department, Wurzburg University, Wurzburg, Germany

Dr. Leopoldo Cancio, Director, U.S. Army Burn Center, USAISR, Fort Sam Houston, TX, U.S.A.

Project Leader: Maureen Dansereau, Critical Care Department, Queen's University, Kingston, ON, Canada







Study Design

Double blind

666 patients
≥18 years of age
Deep 2nd and/or
3rd degree burns
requiring skin
grafting with
TBSA ≥ 20%.

High dose
IV Vitamin C
x 96 hrs

Randomization

Concealed & Stratified by site



POD+Death

Placebo x 96 hrs






Overall Aim

The overall aim of the VICToRY study is to reduce the burden of illness associated with significant burn injury using a naturally occurring substance, vitamin C!





Study Overview







IP Administration and Protocol Violations

Investigational Product (IP)

Active Vitamin C

OR

Control/Placebo
D5W or Saline





IP Dosing and Administration

- + Vitamin C at 200mg/kg/day in divided doses, q6h for up to 96 hours (4 days/16 doses) or until hospital discharge.
- + Patients who weigh more than 150kg will be dosed based on a weight of 150 kg.
- + The total daily dose (mg/day) and single dose (mg/dose) will be calculated by the Central Randomization System (CRS). Additional calculations will be done by pharmacy.
- + Vitamin C will be diluted in D5W or 0.9% NaCl to a concentration between 36 mg/mL and 92 mg/mL.
- + Infusion rate ≤ 100 mg/min.





Timing of Study Intervention

- + IP should start as soon as possible following randomization.
- + IP will be given every 6 hours for 96 hours (16 doses).
- + If IP starts at 2:00 pm on a Tuesday the doses will be:
 - + Tuesday 14:00, 20:00
 - + Wednesday 02:00, 08:00, 14:00, and 20:00
 - + Thursday 02:00, 08:00, 14:00, and 20:00
 - + Friday 02:00, 08:00, 14:00, and 20:00
 - + Saturday 02:00, 08:00





Timing of Study Intervention

- + To ensure the first dose of IP is administered in a timely manner, vitamin C doses may be prepared in advance and are stable for 14 days protected from light and refrigerated.
- + Advanced doses will be prepared using a patient weight of 120 kg.
 - + NOTE: Both vitamin C and placebo bags need to be pre-prepared.
- + Prepared bags must be stored at 2-8° C and protected from light.
- + The bags will be stored in a secure location accessible by the research and lp administration teams.
- + The prepared product expiration must be clearly displayed on each bag.





- + Vitamin C and placebo bags will be placed in separate containers and labelled with a code that can be clearly communicated to the study team via phone, such as 'A' and 'B'.
- + Only the unblinded pharmacy team member(s)/delegate(s) will know which product is in each of the two containers.
- + After the patient is randomized, the pharmacy team member will access the CRS, determine the treatment allocation, and then instruct the study team from which container to retrieve a bag.
 - + To ensure continued blinding of the research team, pharmacy/delegate should periodically rotate the study products and allocate new labels. Pharmacy/delegate team must maintain detailed records of what is in each container and the associated labels at all times.



- + The pharmacy/delegate will also communicate the following:
 - + Total volume of the pre-prepared bag to be infused based on the patient's pre-burn dry weight (per weight entered in the CRS).
 - + Minimum infusion time to ensure a rate ≤ 100 mg/minute.
- + The pharmacy/delegate and research team member must verify together:
 - + Randomization number
 - + Date and Time of randomization
 - + Patient's pre-burn dry weight (as entered in the CRS).





- + The research team will verify with the pharmacy/delegate team member:
 - + The expiration date documented on the bag.
 - + The container from which the bag was taken
- + For patients with a pre-burn dry weight of >120 kg, it is not necessary to infuse more than 1 bag as the initial dose. Record the initial dose as a one-time order. Prepare subsequent doses per the patient's pre-burn dry weight. There is no need to make up for this dose shortage.





- + The pharmacy team will document the following on the pharmacy randomization confirmation:
 - + The container from which the team was instructed to take the bag.
 - + The total volume to be infused that was communicated to the team.
 - + The minimum infusion time communicated to the research team.
- + The research team will document the following on the patient randomization confirmation:
 - + The container from which the bag was taken.
 - + The total volume to be infused that was communicated to them.
 - + The minimum infusion time that was communicated to them.





IP Administration Procedures

- + IP must be administered using infusion pump and can be given through a central or peripheral line.
- + Prepare and hang IV bag per local standard procedures.
 - + Assess the site, flush according to local SOP, clean the port, hang bag.
- + Infuse per pharmacy instructions on the bag (≤100mg/min).
- Do Not co-administer with any other medication.
 - + There is no information available concerning compatibility of IP with other drugs. Therefore, IP should not be co-administered with any other medications.





IP Administration Procedures

- + Infuse IP through a dedicated port:
 - + One port of a triple lumen
 - + Piggyback ONLY with NaCl 0.9% (normal saline) or D5W
 - + May be given through a port containing Ringer's lactate IF the port is flushed before and after infusion of IP





IP Administration Procedures

- + The IP bag and tubing do not need to be protected from light during infusion. According to stability testing, vitamin C concentration between 36 92 mg/mL (diluted in NaCl 0.9% or D5W) is physically and chemically stable for up to 75 hours at room temperature not protected from light.
- + The IV tubing should be primed with IP solution. Be careful not to waste IP when priming the lines.
- + Antibiotic tubing is recommended for IP administration.
- + Following completion of infusion, flush line with NaCl 0.9% to ensure patient receives full dose.





IP & ACU Re-admissions < 24 hours

- + If a participant is transferred out of the ACU before the 16-dose protocol is completed, the treatment will be continued on the step-down unit or ward until the last (16th) dose of investigational product (IP) is administered or the patient is discharged from the hospital, whichever comes first.
- + IP should only be discontinued prior to administration of all 16 doses if the patient is discharged from the hospital.





Infusion Time Examples

kg	mg/day	mg/dose	mL	minutes
Dosing Weight	Daily Dose (based on 200 mg/kg/day)	Single Dose (dosing q6h)	Min volume/dose (based on max conc. 92mg/mL)	Min infusion rate (based on max rate 100mg/min)
50	10,000	2,500	27	25
75	15,000	3,750	41	37.5
100	20,000	5,000	54	50
125	25,000	6,250	68	62.5
150	30,000	7,500	82	75





Interrupted or Missed Dose of IP

- + If possible, do not stop IP for procedures or surgery.
- + If IP is stopped, restart as soon as possible and complete the infusion.
- + Record the start and stop time of the infusion and any interruptions.
- + REDCap allows you to record up to 3 interruptions per dose.

How many times was the dose interrupted?	H 2 V
Initial Start Time	HH:MM 24hr
First Stop Time	HH:MM 24hr
Second Start Time	HH:MM 24hr
Second Stop Time	HH:MM 24hr
Third Start Time	HH:MM 24hr
Final Stop Time	HH:MM 24hr





Interrupted or Missed Dose of IP

- + In the event of a missed dose, please work to make up the missed dose as soon as possible, using the following guidelines:
 - + Do not administer make-up doses with scheduled doses.
 - + Leave at least one hour between the end of one administration and the start of the next.
 - + The patient must be off study product infusion for a minimum of 60 minutes before you begin infusing the next dose.
 - + Delay the start of the next scheduled dose to accommodate the makeup dose.
- + It is vital that all doses of IP are administered.





Unused IP

- + Please follow local procedures for destruction of unused IP.
- + Please follow local procedures for disposal of empty IP bags after the IP has been administered.





IP Non-Compliance

- + Work closely with your bedside clinical staff to ensure the IP is delivered appropriately and consistently.
- + The majority of issues related to IP administration in other studies have been attributable to bedside clinical staff non-compliance.
- + Instruct bedside clinical staff to record and inform the study team of any interruptions in IP administration.
- + Bedside clinical staff should continue administering the study investigational product until they are advised by the study team that the patient is no longer on the study.





Recording Vitamin C Dosing in REDCAP

- + Record each dose of investigational product given.
- + REDCap allows for up to 6 doses to be given each day should you need to make up doses.

Patient ID	nt ID 1001V001		
How many times was the study intervention given today?	H 🗸		
Form Status	0		
Complete?	H 2	plete ~	
Lock this record for this form?			
If locked, no user will be able to edit this record on this form until someone with Lock/Unlock privileges unlocks it.	4 5 Lock		
	6	and go to Grid	





Recording Vitamin C Dosing in REDCAP

- + For each dose indicate if the dose was interrupted.
- + Record the start and stop time of each dose.
- + Indicate if the full volume was infused.

Dose 1	
Was the dose interrupted?	○ Yes
Initial Start Time	HH:MM 24hr
Final Stop Time	HH:MM 24hr
Was the full volume infused?	● Yes ○ No





Incomplete Infusion Record

In the event the full volume was not infused:

- + Record the total volume of the bag as indicated on the label.
- + Record the volume infused.
- + Protocol violations related to incomplete doses will be recorded on the Vitamin C Dosing form.

Dose 1	
Was the dose interrupted?	◯ Yes⊕ No
Initial Start Time	HH:MM 24hr
Final Stop Time	05:05 Now H:M
Was the full volume infused?	○ Yes ● No reset
Total volume provided	100 mL
Partial volume infused	H 70 mL
Please explain why the full dose of investigational product was not received: Note: this is the record of the protocol violation, no need to complete the PV form as well.	Н
	Expand





Glucose Measurements

- + Due to the similar molecular structure of vitamin C and glucose it is possible that capillary blood sugar point-of-care devices will report artificially high glucose measurements. To that end, we are mandating that glucose may only be measured with one of the following 3 systems:
 - 1. Core Lab
 - 2. POC arterial blood gas machine validated in the presence of high plasma concentrations of vitamin C
 - 3. Nova Biomedical StatStrip glucometer (validated accurate in the presence of high plasma concentrations of vitamin C)





Glucometers and Test Strips

- + Nova Biomedical StatStrip glucometers
 - + Are being provided to you for use in the study
 - + Meters and strips will be shipped to you prior to activation





Glucose Testing Post Treatment

- + High plasma concentration of vitamin C may be observed up to 7 days after the last dose of vitamin C is received.
- + For patient's receiving oral hypoglycemics or insulin, one of the 3 validated methods must be used to measure glucose for 7 days after the last dose, or a minimum of 36 hours if the hospital device is validated with the approved method. If validated, the hospital device may be used from that point on as needed.
- + Hospital method is ok in those patients that do NOT require oral hypoglycemics or intravenous insulin.





Questions

